This trial aimed to assess the efficacy of a low concentration chlorhexidine mouth rinse in non-compliant periodontitis patients attending a supportive periodontal programme. This mouthwash was compared with a placebo. Both the patients and clinicians were blind to treatment allocation.
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PERIODONTOLOGY
Fusobacterium nucleatum and Prevotella intermedia showed statistically significant reduction in subgingival counts. With the number of tests carried out, one would consider whether these statistical significance differences are merely the result of chance.
It is important that clinical researchers consider the likely end users of their research. It is therefore commendable that Escribano et al included smokers in this trial as a proportion of patients who suffer from moderate to severe periodontitis would also be likely to smoke. Unfortunately any interpretation of the data for these included patients is complicated by the fact that those who smoke less than 10 cigarettes daily were still included in the non-smoker group.
This trial aimed to assess the efficacy of this new mouth rinse, and the authors report positive findings for reduction in plaque and gingivitis as well as a decline in salivary and gingival sulcus microbial load. In the background to the trial, the authors stated a desire to test the new mouthwash due to the gold standard CHX shortcomings in patient centred outcomes eg. tooth staining etc. This study demonstrated that patients receiving this new mouth wash continued to suffer from these symptoms and did not adequately address this issue in their discussion. Regarding translation of the findings to patient care and use of a reduced concentration CHX, cautious interpretation is advised. Follow on research looking at the actual effectiveness of this new mouth wash compared with the old CHX one would be welcomed.
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